Page 25 - Cf Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pelican Rapids teen, living with cystic fibrosis, designs sailboat for Detroit Lakes public art project Pelican Rapids teenager Logan Hahn is one of more than 80 regional artists contributing their time and talents to the "150 Sails Up in DL" public art project, which will be unveiled at an April 30 "Regatta Party" inside Kent Freeman Arena in Detroit Lakes. But Hahn's story is a unique one: The 15-year-old was born with cystic fibrosis, an inflammatory disease that affects both her lungs and digestive functions. She uses her art to raise funds — and awareness — for area nonpr...

CONTENT: Multimedia with summary FORT WORTH, Texas ― For 36 years, American Airlines has partnered with the Cystic Fibrosis Foundation to host Celebrity Ski Weekend. While this year’s event shifted from the slopes of Beaver Creek, Colorado, to a virtual setting, the importance of raising critical funds to support the foundation’s mission to find a cure for all people with cystic fibrosis (CF) remained unchanged. This year’s virtual event included performances by Warner Records recording artist Teddy Swims and donations from dozens of celebrities and guests. To date, American Airline...

Eaton resident wins $20k, donates half to charity Submitted EATON — Eaton resident Taylor W. was named the January winner of TCC’s Get10Give10 sweepstakes. She was awarded $10,000 during a virtual check presentation in conjunction with TCC’s Eaton store at 1712 N. Barron St. Taylor became eligible for the Get10Give10 sweepstakes after purchasing a new phone from the Eaton TCC location. Throughout 2021, TCC customers who have entered in the sweepstakes will have the chance to win $10,000 to keep and TCC Gives will donate an additional $10,000 to a nonprofit of their choice. Taylor chose...

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin December 22, 2020 01:30 ET | Source: Polyphor AG Polyphor AG Allschwil, SWITZERLAND Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Polyphor’s inhaled murepavadin is a novel class antibiotic that specifically targets Pseudomonas aerug...

MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic 22nd December 2020 Murepavadin is in development as a precision antibiotic to treat chronic Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). It is an outer membrane protein targeting antibiotic (OMPTA) – a novel class of antibiotics discovered by Polyphor and the University of Zurich. The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicine...